COPPER OXYCHLORIDE

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	Cl.2Cu.3HO
Molecular Weight	213.567
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[OH-].[OH-].[OH-].[Cl-].[Cu++].[Cu++]

InChI

InChIKey=SKQUUKNCBWILCD-UHFFFAOYSA-J

InChI=1S/ClH.2Cu.3H2O/h1H;;;3*1H2/q;2*+2;;;/p-4

HIDE SMILES / InChI

Molecular Formula	Cu
Molecular Weight	63.546
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	HO
Molecular Weight	17.0073
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84d61a4-8e7f-4be1-aba6-f633b334aafc | http://www.sciencedirect.com/science/article/pii/S0167488912000158https://www.ncbi.nlm.nih.gov/pubmed/15704330 | https://www.ncbi.nlm.nih.gov/pubmed/12425037 | https://www.ncbi.nlm.nih.gov/pubmed/1599240 | http://www.certisusa.com/pdf-labels/Kocide3000_label.pdf | http://www.pesticideinfo.org/Detail_Chemical.jsp?Rec_Id=PC33524https://www.ncbi.nlm.nih.gov/pubmed/24106015 | https://www.ncbi.nlm.nih.gov/pubmed/20942456http://fs1.agrian.com/pdfs/CORE_7.5_Copper_EDTA_Label.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/16971307https://www.ncbi.nlm.nih.gov/pubmed/8556785 | https://www.ncbi.nlm.nih.gov/pubmed/2135524https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=522.518 | http://www.worldofchemicals.com/chemicals/chemical-properties/cupric-glycinate.htmlhttps://www3.epa.gov/pesticides/chem_search/ppls/019713-00509-20110705.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/6526221http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500013010.pdfhttp://www.emdmillipore.com/US/en/product/Copper-di-ammonium-Titriplex-solution,MDA_CHEM-105217http://www.drugfuture.com/chemdata/schweizer-s-reagent.html | http://pubs.acs.org/doi/abs/10.1021/ed062p878?journalCode=jceda8 | http://pubs.acs.org/doi/abs/10.1021/ed019p356DOI: 10.1107/s0567740869001725 Retrived from http://scripts.iucr.org/cgi-bin/paper?S0567740869001725http://www.drugfuture.com/chemdata/tetraamminecopper-sulfate.html | https://cameochemicals.noaa.gov/chemical/3026
Curator's Comment: description was created based on several sources, including https://www.copper.org/resources/properties/compounds/other_compounds.html | http://www.vitamins-supplements.org/dietary-minerals/copper.php | https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bea888b4-9cc6-49da-89e6-5c273b974ed1

Tetraamminecopper sulfate is a dark blue crystalline solid with a faint odor of ammonia. The primary hazard is the threat to the environment. Immediate steps should be taken to limit its spread to the environment. Used as a pesticide and fungicide, to print fabrics (especially in calico finishing), and to make other copper compounds.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Xanthine dehydrogenase/oxidase 41 Target ID: CHEMBL1075246 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3861140	Inhibitor 8504	3.42 µM [Ki]
Ceruloplasmin 35 Target ID: P00450 Gene ID: 1356.0 Gene Symbol: CP Target Organism: Homo sapiens (Human) Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84d61a4-8e7f-4be1-aba6-f633b334aafc	Binding Agent 1076
Glutathione S-transferase, rat, liver 35 Target ID: Glutathione S-transferase, rat, liver Sources: https://www.ncbi.nlm.nih.gov/pubmed/3008276	Binding Agent 1076
reactive oxygen species metabolic process 68 Target ID: GO:0072593 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8503093	Modulator 846
Escherichia coli 82 Target ID: CHEMBL354 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22098250	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2596
Root caries 35 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8556785 https://www.ncbi.nlm.nih.gov/pubmed/3201109	Preventing	Preclinical	Unknown Approved Use Unknown
Copper deficiency 35 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22444781 https://www.ncbi.nlm.nih.gov/pubmed/20569928	Preventing	Preclinical	Unknown Approved Use Unknown
Copper deficiency 35 Sources: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=522.518	Preventing	Approved 8583	Cupric glycinate Approved Use Indications for use. For beef calves and beef cattle for the prevention of copper deficiency, or when labeled for veterinary prescription use, for the prevention and/or treatment of copper deficiency alone or in association with molybdenum toxicity.
Unknown 2596
Copper deficiency 35 Sources: http://www.bayeranimal.co.nz/en/product-detail.php?p=%203030	Primary	Approved 8583	COPPER•MAX Approved Use Unknown
Unknown 2596
Menkes' kinky hair disease 35 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6520571 https://www.ncbi.nlm.nih.gov/pubmed/4042823 https://www.ncbi.nlm.nih.gov/pubmed/189959	Primary	Not Provided 511	Unknown Approved Use Unknown
Liver cancer 53 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6526221 https://www.ncbi.nlm.nih.gov/pubmed/7326825	Preventing	Preclinical	Unknown Approved Use Unknown
Unknown 2596
Cancer 609 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21039194	Primary	Preclinical	Unknown Approved Use Unknown
Cancer 609 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22812694	Diagnostic	Preclinical	Unknown Approved Use Unknown
Unknown 2596
Copper deficiency 35 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84d61a4-8e7f-4be1-aba6-f633b334aafc	Preventing	Approved 8583	COPPER Approved Use Copper 0.4 mg/mL (Cupric Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN). Administration helps to maintain copper serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
Unknown 2596
Unknown 2596
Copper deficiency 35 Sources: http://www.noahcompendium.co.uk/?id=-446109	Preventing	Approved 8583	COPINOX Approved Use Copinox 4g is indicated for the prevention and treatment of copper deficiency in cattle and sheep.

PubMed

Title	Date	PubMed
The effect of various fluoride compounds on the development of experimental root surface caries in hamsters.	1995 Dec	8556785
The genetics of tasting in mice. VII. Glycine revisited, and the chromosomal location of Sac and Soa.	1995 Oct	8522158
Antioxidant activity of olive pulp and olive oil phenolic compounds of the arbequina cultivar.	2005 Mar 23	15769127
Cu(II) acetate- and Mn(III) acetate-mediated radical reactions of [60]fullerene with ketonic compounds.	2005 Mar 7	15731864
X-ray absorption spectroscopy study of a copper-containing material after thermal treatment.	2006 Apr 17	16257485
A spectroscopic and thermoanalytical study of the mineral hoganite.	2007 May	17321784
Enhanced copper release from pipes by alternating stagnation and flow events.	2007 Nov 1	18044522
Bioavailability of copper from copper glycinate in steers fed high dietary sulfur and molybdenum.	2008 Jan	17911232
Copper(II) acetate-catalyzed addition of arylboronic acids to aromatic aldehydes.	2009 Jan 16	19067580
Copper oxide nanoparticles induce oxidative stress and cytotoxicity in airway epithelial cells.	2009 Oct	19699289
Insight in the transport behavior of copper glycinate complexes through the porcine gastrointestinal membrane using an Ussing chamber assisted by mass spectrometry analysis.	2010 Apr	20413071
Copper-promoted coupling of vinyl boronates and alcohols: a mild synthesis of allyl vinyl ethers.	2010 Feb 3	20067245
A chelator-free multifunctional [64Cu]CuS nanoparticle platform for simultaneous micro-PET/CT imaging and photothermal ablation therapy.	2010 Nov 3	20942456
Anti-ovulatory activity of H2 receptor blockers in albino rabbits--a preliminary study.	2011 Apr	21281096
Rapid free chlorine decay in the presence of Cu(OH)2: chemistry and practical implications.	2011 Oct 15	21868051
Design, synthesis, antioxidant, and anti-breast cancer activities of novel diethyl(alkyl/aryl/heteroarylamino)(4-(pyridin-2-yl)phenyl)methylphosphonates.	2013 May	23589377
Interference of CuO nanoparticles with metal homeostasis in hepatocytes under sub-toxic conditions.	2014	24343273
Synthesis and biomedical applications of copper sulfide nanoparticles: from sensors to theranostics.	2014 Feb 26	24106015
A Facile Strategy for Catalyst Separation and Recycling Suitable for ATRP of Hydrophilic Monomers Using a Macroligand.	2016 Jan	26506506
Dissecting copper homeostasis in diabetes mellitus.	2017 Apr	28276155
Unusual 4-arsonoanilinium cationic species in the hydrochloride salt of (4-aminophenyl)arsonic acid and formed in the reaction of the acid with copper(II) sulfate, copper(II) chloride and cadmium chloride.	2017 Apr 1	28378716
Roles of Copper-Binding Proteins in Breast Cancer.	2017 Apr 20	28425924
Ultrasonic energy enhanced the efficiency of advance extraction methodology for enrichment of trace level of copper in serum samples of patients having neurological disorders.	2017 Jul	28427628
Folic acid-modified and functionalized CuS nanocrystal-based nanoparticles for combined tumor chemo- and photothermal therapy.	2017 Jun	27899044
Amino acid-mediated 'turn-off/turn-on' nanozyme activity of gold nanoclusters for sensitive and selective detection of copper ions and histidine.	2017 Jun 15	28213326
Effects of Excess Copper Ions on Decidualization of Human Endometrial Stromal Cells.	2017 May	27726061

Patents

Sample Use Guides

In Vivo Use Guide

Copper 0.4 mg/mL (Cupric Chloride Injection) contains 0.4 mg copper/mL and is administered intravenously only after dilution. The additive should be diluted in a volume of fluid not less than 100 mL. For the adult receiving total parenteral nutrition, the suggested additive dosage is 0.5 to 1.5 mg copper/day (1.25 to 3.75 mL/day). For pediatric patients, the suggested additive dosage is 20 mcg copper/kg/day (0.05 mL/kg/day). Infants weighing less than 1500 gm may have increased requirements because of their low body reserves and increased requirements for growth.

Route of Administration: Intravenous

In Vitro Use Guide

Human Endometrial Stromal Cells were treated with non-toxic concentrations of copper ions (0-250 uM). mRNA expressions of insulin-like growth factor binding protein (IGFBP-1), prolactin (PRL), Mn-SOD, and FOXO1 were down-regulated during decidualization following the treatments with 100 or 250 uM copper ions. Meanwhile, the amount of malonaldehyde in the supernatant of cells was increased.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:28:07 GMT 2025` Edited by `admin` on `Mon Mar 31 22:28:07 GMT 2025`
Record UNII	76712031PG
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

COPPER OXYCHLORIDE

Systematic Name

English

COPPERCIDE

Preferred Name

English

TRIBASIC COPPER CHLORIDE

Common Name

English

CUPROXOL

Brand Name

English

COPPER CHLORIDE HYDROXIDE (CU2CL(OH)3)

Systematic Name

English

CUPRACOL

Brand Name

English

CUPRITOX

Brand Name

English

BASIC CUPRIC OXYCHLORIDE

Common Name

English

DICOPPER(II) CHLORIDE TRIHYDROXIDE

Common Name

English

COPPER CHLORIDE (CU2(OH)3CL)

Common Name

English

OXYCLOR

Brand Name

English

COPPER OXYCHLORIDE [ISO]

Common Name

English

COPRANTOL

Brand Name

English

CUPROVIT

Brand Name

English

CUPRASOL

Brand Name

English

Classification Tree Code System Code

EPA PESTICIDE CODE

8001